Caterpillar Inc vs TransMedics Group Inc — how do they compare? Caterpillar Inc trades at $923.6 (market cap $429.89B), while TransMedics Group Inc trades at $75.36 (market cap $2.58B). The key difference: Caterpillar Inc is far larger — about 166.6× TransMedics Group Inc's market cap, and Caterpillar Inc pays a 0.7% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CAT | TMDX | |
|---|---|---|
Market Cap | $429.89B | $2.58B |
Sector | Industrials | Technology |
52-Week High | $1.06K | $150.42 |
52-Week Low | $404.64 | $61.99 |
Enterprise Value | $468.88B | $2.98B |
Dividend Yield | 0.7% | — |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $931.47, down 2.2% on the day, but has gained 51% year-to-date, driven by strong earnings beats and AI-related infrastructure demand. The stock shows a bullish moving average signal but neutral overall technicals, with support near $922. Revenue reached $67.59 billion in 2025, with a net income margin of 13.33%, though valuation multiples like a P/E of 46.48 appear elevated. Recent news highlights its role in the AI data center boom, with the Power & Energy segment seeing significant backlog growth.
The outlook remains positive given analyst consensus and AI-driven tailwinds, but high valuation and exposure to economic cycles pose risks. With 55% of analysts rating it a Buy and a consensus price target of $1,030, upside potential exists, though investors should weigh margin pressures and debt levels against growth catalysts from data center and infrastructure spending.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Trailing returns across standard periods
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →